Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways.

Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation. The company is evaluating verekitug as a potential treatment for inflammatory respiratory conditions, including asthma and chronic rhinosinusitis with nasal polyps.

Upstream Bio advances its programs through clinical development and collaborations with research and healthcare organizations. The company is based in the United States and focuses on serving patients with significant unmet needs in immune-mediated and inflammatory diseases. As a clinical-stage biotechnology company, its operations remain primarily centered on research, clinical trials and the development of potential future therapies.

Key Stats

• Today's Range: $4.67 to $5.10
• 50-Day Range: $5.04 to $7.51
• 52-Week Range: $4.66 to $33.68
• Volume: 542,552 shs
• Average Volume: 830,502 shs
• Market Capitalization: $263.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.67
• Consensus Rating: Hold

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 55% of companies evaluated by MarketBeat, and ranked 416th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Upstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Upstream Bio has a consensus price target of $29.67, representing about 530.5% upside from its current price of $4.71.

Amount of Analyst Coverage

Upstream Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Upstream Bio are expected to grow in the coming year, from ($2.84) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Upstream Bio is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Upstream Bio is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Upstream Bio has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.81% of the float of Upstream Bio has been sold short.

Short Interest Ratio / Days to Cover

Upstream Bio has a short interest ratio ("days to cover") of 6.84.

Change versus previous month

Short interest in Upstream Bio has recently increased by 9.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Upstream Bio has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Upstream Bio this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Upstream Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 75
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Upstream Bio: $29.67
• High Price Target: $50.00
• Low Price Target: $9.00
• Potential Upside/Downside: +522.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.44 million
• Net Margins: -4,955.67%
• Pretax Margin: -4,955.67%
• Return on Equity: -48.40%
• Return on Assets: -46.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.99
• Quick Ratio: 27.99

Sales & Book Value

• Annual Sales: $2.85 million
• Price / Sales: 91.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.29 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 54,770,000
• Free Float: 45,756,000
• Market Cap: $260.98 million
• Optionable: N/A
• Beta: 1.38